Summit Biolabs is a commercial-stage molecular diagnostics company harnessing the power of liquid-biopsy to rapidly detect diseases like COVID-19, Influenza A/B, bacterial infections, and sexually transmitted diseases. Summit Biolabs was spun out of the University of Colorado Anschutz Medical Campus. The company leveraged its competencies in viral detection in saliva and direct-to-PCR platform technology to help combat the pandemic. Summit developed and deployed two highly accurate, rapid, and high-throughput PCR tests for COVID-19 diagnosis. These commercial laboratory-developed tests eliminate the time and cost of nucleic acid extraction, while significantly improving the turn-around-time for results. Summit Biolabs has ongoing test development projects capitalizing on their direct-to-PCR platform technology for other indications. The company's high-complexity, molecular diagnostics CLIA-certified laboratory is located at Bioscience 3 on the Fitzsimons Innovation Campus in Aurora, Colorado.